A combined nanotherapeutic approach targeting farnesoid X receptor, ferroptosis, and fibrosis for nonalcoholic steatohepatitis treatment

• প্রধান লেখক: Jiangtao Fu (লেখক), Pingping Zhang (লেখক), Zhiguo Sun (লেখক), Guodong Lu (লেখক), Qi Cao (লেখক), Yiting Chen (লেখক), Wenbin Wu (লেখক), Jiabao Zhang (লেখক), Chunlin Zhuang (লেখক), Chunquan Sheng (লেখক), Jiajun Xu (লেখক), Ying Lu (লেখক), Pei Wang (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Elsevier, 2024-05-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist with favorable effects on fatty and glucose metabolism, has been considered the leading candidate drug for nonalcoholic steatohepatitis (NASH) treatment. However, its limited effectiveness in resolving liver fibrosis and lipotoxicity-induc...